Myovant CEO Says Buoyant IPO Reflects High Interest In Women's Health

Recently created biotech Myovant has floated on the New York Stock Exchange to raise capital to progress its two lead candidate therapies; one for women's health conditions and another for prostate, and says Pfizer's sizable stake in the IPO reflects rising interest in these therapy areas.